Main Page Aims and Scope Editorial Board Instructions to Authors Contact

Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease [Eurasian J Pulmonol]
Eurasian J Pulmonol. 2017; 19(1): 51-53 | DOI: 10.5152/ejp.2016.14622  

Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease

Şenay Yılmaz, Güntülü Ak, Muzaffer Metintaş
Department of Chest Diseases, Eskişehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Osmangazi University School of Medicine, Eskişehir, Turkey

Lung adenocarcinoma (LA) may occur with a radiographic appearance of localized tumor in the parenchyma or with diffuse parenchymal infiltration as interstitial lung disease (ILD). In our country, erlotinib is a tyrosine kinase inhibitor used in Epidermal Growth Factor Receptor (EGFR) mutation-positive patients who are resistant to first-line chemotherapy. A 48-year-old patient presented to our hospital with weakness and shortness of breath on exertion. Mediastinal enlargement and bilateral multinodules were observed in the chest X-ray. Ordinary blood laboratory values and arterial blood–gas analysis findings were normal. Lung function tests showed moderate restrictive ventilation and reduction of diffusing capacity based on the predicted value. A thorax computed tomography scan showed multiple mediastinal lymphadenopathies and bilateral diffuse perilymphatic nodule spread. The patient diagnosed with LA on the basis of endo–bronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Because of bilateral diffuse involvement of the lung, platinum-based combination chemotherapy was recommended. The progression of disease had occurred after two cycles, and a second-line treatment with erlotinib (150 mg/day) was initiated. A decrease in all lesions was observed in patient follow-up. The treatment with erlotinib was well tolerated. There was no adverse event for 6 months. This case was presented for the choice of LA that mimicked ILD and for the significant clinical and radiological responses to erlotinib in patients with EGFR mutation.

Keywords: Erlotinib, interstitial lung disease, lung adenocarcinoma

Şenay Yılmaz, Güntülü Ak, Muzaffer Metintaş. Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease. Eurasian J Pulmonol. 2017; 19(1): 51-53

Corresponding Author: Şenay Yılmaz, Türkiye

Full Text PDF
Download citation
Reference Manager
Share with email
Send email to author

Similar articles
Google Scholar

Quick Search


Copyright © 2016 Turkish Respiratory Society. All rights reserved
Bu web sitesi sağlık profesyonellerine yöneliktir. İçeriğindeki yazılar ve dökümanlar hekim veya eczacı görüşü yerine geçmez. Sitenin kullanımıyla ilgili her türlü sorumluluk kullanıcıya/ziyaretçiye aittir.

LookUs & Online Makale